Skip to main content

Table 3 Post-transplant 2-year outcomes

From: Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party

 

NRM

RI

Extensive GVHD

GRFS

LFS

OS

No-ATG

17.3% [13.3–21.7]

27.2% [22.4–32.1]

26.3% [21.2–31.6]

39.6% [34–45.1]

55.4% [49.8–61]

58.9% [53.2–64.6]

ATG

10.7% [7.7–14.2]

22.5% [15.1–30.8]

7.6% [3.5–13.7]

60.1% [51–69.3]

66.8% [58.1–75.6]

71.8% [63.4–80.2]

p value

0.149

0.226

4.7 × 10−5

0.00016

0.044

0.049

  1. ATG anti-thymocyte globulin, GRFS GVHD and relapse-free survival, LFS leukemia-free survival, NRM non-relapse mortality, OS overall survival, RI relapse incidence